If process is product, mustn’t quality be top of strategy in Indian pharma?

  In the tsunami of Bihar election news, a significant development got swept away last weekend. It was the announcement by Dr Reddy’s Laboratories that three of its manufacturing plants in India had received US FDA warning letters. Today, Mint reports that the American regulator has sought third party audit across the pharma company’s entire […]

Monsanto has plumped for services, big data to expand in India. Will farmers trust it?

When Monsanto, agri-tech company the world loves to hate, bought the weather data company Climate Corps for $930 million last year, few believed it would start peddling its data services in India any time soon. Less than a year from that acquisition, Monsanto India’s new chief executive Shilpa Divekar Nirula, who took charge in August, […]

BJP, Ayurgenomics, and the dangerous mixing of science & politics

Indian elections are insipid when it comes to debates and discussions around big, futuristic ideas. Neither political parties discuss their vision in any meaningful detail nor does the public ask for it. But a few days ago some publications picked up an exotic-sounding term, “Ayurgenomics”, from the BJP manifesto. It said:   “We will start […]

BJP, Ayurgenomics, and the dangerous mixing of science & politics

Indian elections are insipid when it comes to debates and discussions around big, futuristic ideas. Neither political parties discuss their vision in any meaningful detail nor does the public ask for it. But a few days ago some publications picked up an exotic-sounding term, “Ayurgenomics”, from the BJP manifesto. It said:   “We will start […]

Why the new director of IISc has his role cut out

  In the din and bustle, hope and anxiety, of the national elections, one big event which is being sidelined is that India’s largest and one of the oldest institutions is going to have a new director. Even if most of the public couldn’t care less about a research institution’s new director, it is a […]

The many downsides and one upside of India’s clinical trials mess

  Hardly a week goes by when the term ˜clinical trial” is not in news, and unfortunately, in recent times, it’s been more for the wrong reasons. On January 9, Financial Times reported Novartis will face a criminal investigation for wrongful marketing practices of its popular blood pressure medicine Diovan. Then there was this detailed […]

The many downsides and one upside of India's clinical trials mess

  Hardly a week goes by when the term ˜clinical trial” is not in news, and unfortunately, in recent times, it’s been more for the wrong reasons. On January 9, Financial Times reported Novartis will face a criminal investigation for wrongful marketing practices of its popular blood pressure medicine Diovan. Then there was this detailed […]